Seedchrony Total Addressable Market 3.75 Billion €
The global In Vitro Fertilization (IVF) market is experiencing unprecedented growth, driven by rising infertility rates, demographic shifts, and advancements in assisted reproductive technologies. Valued at $25 billion in 2023, the market is projected to surpass $50 billion by 2030, growing at a CAGR of over 9%. Increasing accessibility, insurance coverage expansion, and innovation in embryo selection and cryopreservation further drive market demand.
Currently, over 3 million IVF cycles are performed worldwide each year, with demand expected to rise due to delayed parenthood and declining fertility rates. As technology advances, success rates continue to improve, making IVF a mainstream solution for millions of couples globally.
At the forefront of this transformation is Seedchrony, a groundbreaking device poised to become the new standard of care in IVF for embryo transfer. With a total addressable market (TAM) of $3.65 billion, Seedchrony represents a disruptive opportunity in precision reproductive medicine. Its adoption across fertility clinics worldwide underscores the shift toward enhanced clinical outcomes, efficiency, and patient success rates.
The convergence of cutting-edge technology and rising global demand creates a unique window for strategic investment. Now is the time to be part of the future of fertility.
Market Entrance
Spain 2027
Seedchrony launching phase is in Spain, country that represents x% of IVF cycles in Europe
EU & UK 2028
In the scale up phase ....
US & Canada 2029
On penetration phase ...
Australia & Japan 2030
Market witnessing significant growth due to increased awareness of infertility solutions, the rise of same-sex couples, single methods, and egg freezing procedures
Public Sector 2031
Seedchrony is a First-in-class device that reads biomarker data in the uterus the same day of transfer or day before